Overview
Technology transfer and consulting services for research impact.
Founded
1987
Deals ยท 12mo
3
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
MoA Technology | Jul 2026Participated | $30 MSeries C | |
Scripta Therapeutics | Nov 2025Participated | $12 MSeed | |
Wild Bioscience | Oct 2025Participated | $59 MSeries A | |
Ultromics | Jul 2025Participated | $55 MSeries C | |
Diffblue | Oct 2024Participated | $6 MOther Equity | |
Louisa AI | Mar 2024Participated | $5 MSeed | |
Caristo Diagnostics | Apr 2023Participated | $16 MSeries A | |
Brill Power | Jul 2022Participated | $10 MSeries A | |
Infersens | May 2022Participated | $1 MOther Equity | |
OMass Therapeutics | Apr 2022Participated | $95 MSeries B | |
Brainomix | Dec 2021Participated | $21 MSeries B | |
Oxford VR | Feb 2020Participated | $13 MSeries A | |
MoA Technology | Jul 2026Participated | $30 MSeries C | |
Scripta Therapeutics | Nov 2025Participated | $12 MSeed | |
Wild Bioscience | Oct 2025Participated | $59 MSeries A | |
Ultromics | Jul 2025Participated | $55 MSeries C | |
Diffblue | Oct 2024Participated | $6 MOther Equity | |
Louisa AI | Mar 2024Participated | $5 MSeed | |
Caristo Diagnostics | Apr 2023Participated | $16 MSeries A | |
Brill Power | Jul 2022Participated | $10 MSeries A | |
Infersens | May 2022Participated | $1 MOther Equity | |
OMass Therapeutics | Apr 2022Participated | $95 MSeries B | |
Brainomix | Dec 2021Participated | $21 MSeries B | |
Oxford VR | Feb 2020Participated | $13 MSeries A |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 2 |
| Series A | 0 | 5 |
| Series B | 0 | 3 |
| Series C+ | 0 | 3 |
| Other Equity | 0 | 5 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Apr '10 | 1 |
| May '10 | 0 |
| Jun '10 | 0 |
| Jul '10 | 0 |
| Aug '10 | 0 |
| Sep '10 | 0 |
| Oct '10 | 0 |
| Nov '10 | 0 |
| Dec '10 | 1 |
| Jan '11 | 0 |
| Feb '11 | 0 |
| Mar '11 | 0 |
| Apr '11 | 0 |
| May '11 | 0 |
| Jun '11 | 0 |
| Jul '11 | 0 |
| Aug '11 | 0 |
| Sep '11 | 0 |
| Oct '11 | 0 |
| Nov '11 | 0 |
| Dec '11 | 0 |
| Jan '12 | 0 |
| Feb '12 | 0 |
| Mar '12 | 0 |
| Apr '12 | 0 |
| May '12 | 0 |
| Jun '12 | 0 |
| Jul '12 | 0 |
| Aug '12 | 0 |
| Sep '12 | 0 |
| Oct '12 | 0 |
| Nov '12 | 0 |
| Dec '12 | 0 |
| Jan '13 | 0 |
| Feb '13 | 0 |
| Mar '13 | 0 |
| Apr '13 | 0 |
| May '13 | 0 |
| Jun '13 | 0 |
| Jul '13 | 0 |
| Aug '13 | 0 |
| Sep '13 | 0 |
| Oct '13 | 0 |
| Nov '13 | 0 |
| Dec '13 | 0 |
| Jan '14 | 0 |
| Feb '14 | 0 |
| Mar '14 | 0 |
| Apr '14 | 0 |
| May '14 | 0 |
| Jun '14 | 0 |
| Jul '14 | 0 |
| Aug '14 | 0 |
| Sep '14 | 0 |
| Oct '14 | 0 |
| Nov '14 | 0 |
| Dec '14 | 0 |
| Jan '15 | 0 |
| Feb '15 | 0 |
| Mar '15 | 0 |
| Apr '15 | 0 |
| May '15 | 0 |
| Jun '15 | 0 |
| Jul '15 | 0 |
| Aug '15 | 0 |
| Sep '15 | 0 |
| Oct '15 | 0 |
| Nov '15 | 0 |
| Dec '15 | 0 |
| Jan '16 | 0 |
| Feb '16 | 0 |
| Mar '16 | 0 |
| Apr '16 | 0 |
| May '16 | 0 |
| Jun '16 | 0 |
| Jul '16 | 0 |
| Aug '16 | 0 |
| Sep '16 | 0 |
| Oct '16 | 0 |
| Nov '16 | 0 |
| Dec '16 | 0 |
| Jan '17 | 0 |
| Feb '17 | 0 |
| Mar '17 | 0 |
| Apr '17 | 0 |
| May '17 | 0 |
| Jun '17 | 0 |
| Jul '17 | 0 |
| Aug '17 | 0 |
| Sep '17 | 0 |
| Oct '17 | 0 |
| Nov '17 | 0 |
| Dec '17 | 0 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 1 |
| May '18 | 1 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 1 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 0 |
| Jul '19 | 1 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 1 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 1 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 1 |
| May '22 | 1 |
| Jun '22 | 0 |
| Jul '22 | 1 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 1 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 1 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 1 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 1 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 1 |
| Nov '25 | 1 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 1 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 14 |
| AI & Machine Learning | 8 |
| Clean Energy & Sustainability | 2 |
| Data, Analytics & IT | 2 |
| Manufacturing | 2 |
| Food & Agriculture | 2 |
| Professional Services | 2 |
| Enterprise Software | 1 |
| AR/VR | 1 |
| Space & Frontier Tech | 1 |
| Transportation & Logistics | 1 |
| Networks, Cloud & Communication | 1 |
| Marketing & Advertising | 1 |
| Developer Tools | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 3 |
| $5M-$10M | 4 |
| $10M-$25M | 5 |
| $25M-$50M | 3 |
| $50M-$100M | 3 |
| $100M-$250M | 0 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Europe | 17 |
| United States | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Oxford Science Enterprises | 11 |
| Parkwalk Advisors | 5 |
| Google Ventures | 3 |
| AlbionVC | 2 |
| Boehringer Ingelheim | 2 |
| Borealis Ventures | 2 |
| IP Group | 2 |
| Legal & General | 2 |
| Oxford Investment Consultants | 2 |
| Oxford Technology and Innovations | 2 |
| Agri Investment Fund | 1 |
| Allegis Capital | 1 |
| Apollo Health Ventures | 1 |
| Barclays | 1 |
| BGF | 1 |
| BlueCross BlueShield Venture Partners | 1 |
| Braavos Capital | 1 |
| Chimera Partners | 1 |
| Citi Institutional Strategic Investments | 1 |
| Clarus Ventures | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 0 | 0% |
| Participating | 18 | 100% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 0 | 0% |
| Co-led | 0 | 0% |
Lead dynamics requires at least one led deal in this range
Team
Chief Operating Officer
Head of Investments and New Ventures
Startup Mentor
Marketing and Communications Manager
Head of Operations
Incubator Manager
